NCT06648057 2026-03-18
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
Recruiting
Clinical Trials
24 trialsNCT06859684 2026-03-09
HAIC-quad
West China Hospital
Phase 2 Recruiting
NCT07432568 2026-02-25
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07070700 2025-08-12
CASTLE-ZS-02
Fudan University
Phase 2 Recruiting
NCT03781934 2025-07-01
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Medivir
Phase 1/2 Completed
NCT06643208 2025-06-26
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Fujian Provincial Hospital
Recruiting
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06208462 2025-03-03
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05010681 2025-02-27
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
Phase 2 Recruiting
NCT05010668 2025-02-21
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2 Completed
NCT05532059 2025-02-10
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06192797 2024-11-05
CCGLC-013
Tongji Hospital
Phase 2 Recruiting
NCT06648525 2024-10-18
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Harbin Medical University
Phase 2 Not yet recruiting
NCT06505486 2024-07-17
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
NCT06298968 2024-07-03
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT06417606 2024-05-22
Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma
Tongji Hospital
Phase 4 Not yet recruiting
NCT06192784 2024-01-09
CCGLC-012
Tongji Hospital
Phase 2 Unknown
NCT03895970 2023-03-29
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Peking Union Medical College Hospital
Phase 2 Completed
NCT04211168 2023-03-29
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03951597 2021-07-07
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04656249 2021-06-04
LENABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT03801499 2020-05-21
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Withdrawn
NCT03779100 2019-01-28
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
Sun Yat-sen University
Phase 2 Suspended